Validating Single-Use Systems in Biopharma: Key Requirements and Emerging Expectations

person-image
Jo Doucet, Division Head Qualification/Validation at QbD Group
Learn the key requirements for validating Single-Use Systems, with guidance on supplier control, compliance, and Extractables & Leachables risk management.
Validating Single-Use Systems in Biopharma: Requirements & Expectations
4:46

 

Single-Use Systems (SUS) have become a fundamental component of modern biopharmaceutical manufacturing. Their flexibility, reduced cleaning requirements, and rapid deployment make them ideal for dynamic processes such as cell culture, buffer preparation, purification steps, and fill–finish operations.

However, as SUS rely on polymer-based materials, Quality and Validation teams must not only ensure robust functional validation but also consider the potential chemical risks associated with Extractables & Leachables (E&L).

Regulators increasingly expect manufacturers to demonstrate control over both dimensions — operational performance and material compatibility — making the validation of SUS a multidimensional task where quality, compliance, and E&L risk management converge.

 

1. Supplier Qualification and Material Traceability

The foundation of SUS validation begins with supplier qualification. Since SUS are manufactured using complex supply chains, Quality teams must ensure that vendors provide:

  • Complete material specifications
  • Certificate of compliance for process-contact components
  • Change control mechanisms
  • Robust quality systems and audit readiness

Traceability is critical. Regulators expect manufacturers to demonstrate full visibility into the materials that come into contact with process fluids. When components are preassembled, pre-sterilized, or sourced from multiple suppliers, the validation burden increases significantly.

2. Ensuring Fitness for Intended Use

Validating SUS is not just about confirming functionality — it is about proving that each component is suitable for its specific process application. This includes evaluating:

  • Mechanical integrity (pressure, torque, sealing, tensile strength)
  • Sterility assurance and sterilization compatibility
  • Integrity testing before and after use
  • Compatibility with process fluids, operating conditions, and mixing parameters

Regulators expect documented evidence that the SUS configuration used in manufacturing aligns with the conditions assessed during validation. Any deviation (e.g., different tubing type, new filter model, alternate connector) can require requalification or additional justification.

3. Quality Documentation and Inspection Readiness

A complete validation package must include clear, traceable documentation that supports decision-making. This typically involves:

  • Design qualification (DQ) based on process requirements
  • Installation qualification (IQ) including component identification
  • Operational qualification (OQ) demonstrating functional performance
  • Standard operating procedures for assembly, handling, and disposal
  • Risk assessments aligned with ICH Q9(R1) principles

Auditors routinely request evidence that SUS have been evaluated systematically, that change controls are in place, and that Quality has visibility over supplier reliability and component consistency.

4. Where Extractables & Leachables (E&L) Strengthen the Validation Framework

While mechanical and functional validation ensure the system works as intended, they do not address the chemical risks associated with polymer-based materials. This is where Extractables & Leachables (E&L) assessments become a crucial complement to the overall validation strategy.

SUS materials can release chemical compounds under certain temperature, pH, and process conditions. Regulators increasingly expect manufacturers to demonstrate that these compounds:

  • Are identified and assessed
  • Pose no risk to product quality or patient safety
  • Are evaluated using justified, traceable toxicological frameworks
  • Are supported by appropriate supplier or custom studies

However, interpreting extractables datasets — often hundreds of pages — requires specialized expertise in both analytical chemistry and toxicology.

 

Conclusion

Single-Use Systems bring tremendous advantages to biopharmaceutical manufacturing, but they also introduce new validation and compliance responsibilities. By building a robust validation framework — and complementing it with accurate E&L assessment when needed — Quality teams can confidently demonstrate control, maintain inspection readiness, and protect product integrity.

Need expert support in single-use system validation? 

QbD Group supports Quality and Validation teams by independently reviewing supplier E&L data, identifying gaps, and providing toxicological risk assessments performed by certified experts.

We develop process-specific justifications that avoid unnecessary testing and deliver audit-ready documentation that fits seamlessly into validation files, ensuring SUS qualification is both scientifically sound and fully compliant with regulatory expectations.

Let’s work together to future-proof your biopharmaceutical operations.  

Contact us today. 

 

Stay ahead in life sciences

Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.

Circles-banner-short

Discover more expert content

preview_image
Case study

Validating a Complex Autoclave Load to Enhance Sterilization Efficiency

Discover how QbD Group helped a pharmaceutical facility in Barcelona optimize and validate a complex autoclave load, improving sterilization efficiency and manufacturing flexibility.
preview_image
Case study

Scalable MSAT validation support for seamless compliance & efficiency

Discover how QbD Group helped a global pharmaceutical company address fluctuating validation demands across multiple teams.
preview_image
Case study

Guiding a global biotech company through ATMP facility qualification

Discover how QbD Group supported a global biotech company in commissioning and qualifying two ATMP therapy production sites, ensuring compliance and efficiency.
preview_image
Whitepaper

Achieving laboratory compliance

This whitepaper explores the multifaceted aspects of laboratory compliance, including data integrity, quality control measures, and regulatory adherence.
preview_image
Whitepaper

New GMP Facility Qualification: set-up, process and best practices

This whitepaper delves into the challenges of establishing a new GMP facility, focusing on potential pitfalls and best practices. Download now.
preview_image
Whitepaper

Analytical Method Validation

In this whitepaper, we will give an overview of the criteria to consider when validating your analytical method.
preview_image
Case study

Ensuring timely launch: QbD Group's role in establishing a hemophilia drug production line

QbD Group has facilitated the launch of a new drug production line for treating hemophilia, overseeing the qualification of over 100 pieces of small-scale supporting equipment.